# Pharma seeks CDSCO clarity on batch solvent rule for exports 2026-11-09T02:36:57+00:00 | Governance | Indian Opinion Desk Corroboration: 2 independent outlets The Indian pharmaceutical industry has sought clarification from the Central Drugs Standard Control Organisation (CDSCO) on whether its new batch-wise digital clearance requirement for high-risk pharmaceutical solvents applies to export-oriented manufacturers. Industry executives warned that an unclear scope could disrupt solvent supplies and affect medicine availability, particularly for smaller firms supplying rural markets. Under the directive, CDSCO instructed state drug controllers to require manufacturers and suppliers of specified solvents to register on the Online National Drugs Licensing System and obtain a no-objection certificate for every batch. Industry representatives said the order does not distinguish between solvents for domestic and export use, creating the risk of inconsistent enforcement among state authorities. CDSCO had not responded to queries from Business Standard as of publication on 8 November. Smaller manufacturers, which hold limited inventories, are seen as most vulnerable to processing delays from understaffed state drug departments. The directive follows heightened scrutiny after 24 children died in Madhya Pradesh in 2025, linked to Coldrif cough syrup containing high levels of diethylene glycol, a toxic industrial chemical sometimes used illegally as a solvent substitute. ## Indian Opinion Analysis Medical Dialogues leads with the industry’s call for CDSCO clarity on batch-wise solvent clearance and the risk of supply disruptions for domestically focused and small manufacturers, citing supply-chain bottlenecks as the central problem. Hindustan Times’s piece, by a Senores executive, is a standalone growth-opinion piece on CDMOs that does not cover the CDSCO directive or supply concerns, it is not reporting on the same event. The only shared factual ground is the pharmaceutical sector’s regulatory environment. Medical Dialogues provides straight, unslanted reporting of industry anxiety and official silence, making its framing neutral-report, while Hindustan Times offers no story-specific stance. The uniform coverage on the CDSCO story comes solely from Medical Dialogues, which reports no government response yet, the next concrete point is the unanswered status of industry queries to CDSCO. ## Coverage Coverage: 2 sources, 2 neutral - medicaldialogues.in (neutral report) Leads with industry requests and supply disruption fears, no government response - hindustantimes.com (neutral report) Not on the CDSCO story, standalone CDMO growth opinion piece with no stance on this event This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Tags: Arushi Jain, CDSCO, drugs and cosmetics act, Madhya Pradesh, Rishi Agrawal Canonical: https://indianopinion.org/pharma-seeks-cdsco-clarity-on-batch-solvent-rule-for-exports/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/pharma-seeks-cdsco-clarity-on-batch-solvent-rule-for-exports/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/